Immunocore Holdings plc
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Immunocore Holdings plc is a commercial-stage biotechnology company specializing in the development of T-cell receptor (TCR) bispecific immunotherapies, primarily targeting cancer, infectious diseases, and autoimmune conditions. The company’s product portfolio includes its lead approved therapy, KIMMTRAK (tebentafusp), indicated for HLA-A*02:01-positive patients with unresectable or metastatic uveal melanoma. Beyond KIMMTRAK, Immunocore is advancing a pipeline comprising multiple clinical-stage candidates including IMC-R117C (PIWIL-1) for advanced solid tumors such as colorectal cancer; IMC-P115C (PRAME-HLE-A02) targeting tumors expressing PRAME; IMC-M113V and IMC-I109V for potential functional cures of HIV and hepatitis B virus respectively; as well as IMC-T119C, IMC-S118AI, and IMC-U120AI addressing solid tumors, type 1 diabetes, and atopic dermatitis. The company leverages its proprietary, off-the-shelf ImmTAX (Immune mobilizing monoclonal TCRs Against X disease) platform to develop these therapies. Founded in 2008 and headquartered in Abingdon, United Kingdom, Immunocore operates primarily in the US and UK markets, with regulatory approvals and commercial launches spanning 39 countries for KIMMTRAK. Recent strategic developments include a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab for advanced cutaneous melanoma. In 2024, Immunocore expanded KIMMTRAK launches into 14 additional countries, reaching 24 countries globally by year-end, driving 30% year-on-year net sales growth and maintaining 11 consecutive quarters of revenue increase. The company also announced a strategic collaboration with Exogene to utilize artificial intelligence for accelerating TCR discovery, enhancing lead candidate generation. Immunocore is progressing multiple Phase 3 trials for cutaneous and adjuvant melanoma with expected data readouts in 2026. They plan to file clinical trial applications for IMC-U120AI in 2026, marking their first non-HLA-restricted universal therapy program. Immunocore’s industry focus lies in biotechnology and life sciences with a core emphasis on innovative immunotherapeutics designed to address significant unmet medical needs. Its customer base primarily encompasses oncology and immunology patients worldwide. The company employs a multidisciplinary approach combining bispecific TCR therapeutics with AI-driven collaboration to accelerate development timelines and broaden therapeutic reach across cancer, infectious, and autoimmune disease segments. Immunocore Holdings plc remains commercially active with a strong commitment to expanding global access to its approved product KIMMTRAK while advancing a robust pipeline aimed at functional cures and novel immunotherapies across multiple disease areas, maintaining its position as a leader in TCR bispecific immune medicines.
Immunocore: KIMMTRAK Is Becoming A Cash Engine For A Much Larger TCR Platform
Is it a Good Idea to Invest in Immunocore Stock Right Now?
4 Biotech Stocks Investors Should Watch in 2026
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet
Immunocore reports first quarter financial results and provides a business update
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Recommendation of “Hold” by Brokerages
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Here Are Monday’s Top Wall Street Analyst Research Calls: Alnylam Pharmaceuticals, Circle Internet, Fifth Third Bancorp, Intuit, ServiceNow, Qualcomm, Trade Desk, and More
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Recommendation of “Moderate Buy” from Analysts
Immunocore to present at upcoming investor conferences
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
Immunocore (IMCR) Upgraded to Strong Buy: Here's Why
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of “Moderate Buy” from Brokerages